Clinical Trials Logo

Clinical Trial Summary

This study investigates the effects of a 12-week high-intensity interval training (HIT) on exercise tolerance, functional status and quality of life in patients with chronic heart failure with preserved ejection fraction (HFpEF), in comparison to a control group continuing to undergo usual care.

Clinical Trial Description

Heart failure (HF) with preserved ejection fraction (HFpEF) occurs in about 50% of all HF patients. Remodeling and fibrosis stimulated by inflammation appear to be main factors for the progression of HFpEF. Furthermore, iron deficiency (ID) has been recognized to be a common comorbidity in HFpEF. The lack of prognostic treatment options in HFpEF urgently calls for new therapeutic approaches. While beneficial effects of exercise training and iron substitution have been demonstrated in HF with reduced ejection fraction, they have not yet been evaluated in HFpEF. Therefore, the aim of this study is to investigate the effects of high-intensity interval training (HIT) in HFpEF patients with optimally adjusted iron values.

The proposed study will be a prospective, single-blind, randomized controlled trial in a primary care setting including 98 patients with stable HFpEF. Patients will undergo 3 study visits (a screening visit, a baseline visit and a post-intervention visit) including measurements of disease-specific biomarkers (using blood samples), cardiac and arterial vessel structure and function (using electrocardiogram, echocardiography and pulse wave velocity), exercise tolerance (using spiroergometry), habitual physical activity (using accelerometry) and QoL. After the screening visit, patients with a functional or absolute ID will undergo iron substitution until sufficient iron levels are reached (up to max. 12 weeks), in order to ensure comparable baseline conditions for the training intervention. The study examinations will be repeated after 12 weeks in both, initially iron deficient and non-iron deficient patients (baseline visit). Patients will then be randomized to either the intervention or control group, stratified by initial iron-deficiency status. The intervention group (n=49) will attend a supervised 12-week HIT on a bicycle ergometer, while the control group (n=49) will be advised to continue usual care and follow health recommendations for patients with chronic HF. After 12 weeks, the study measurements will be repeated in all patients (intervention and control group) in order to monitor the effects of the intervention (post-intervention visit). At 6 months, 1, 2 and 3 years after the last study visit, telephone interviews will be performed to assess medical outcomes and QoL.

Outlook: This study is expected to add important knowledge about the potential utility of a novel treatment strategy in HFpEF patients, which may help to improve both, QoL and functional status. Moreover, the analysed biomarkers might be able to provide further insight into prognosis and pathogenesis of HFpEF. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03184311
Study type Interventional
Source Cantonal Hosptal, Baselland
Contact Thomas Dieterle, MD
Phone +41 61 925 32 30
Status Not yet recruiting
Phase N/A
Start date October 1, 2017
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03251183 - Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF N/A
Active, not recruiting NCT02459626 - Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Recruiting NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT02638961 - Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF N/A
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States N/A
Recruiting NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Recruiting NCT03289481 - Treatment of HFpEF With Nitrate Supplement N/A
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03186833 - The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study. N/A
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Recruiting NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea N/A
Not yet recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Recruiting NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure N/A
Recruiting NCT02923609 - Cell Therapy in HFpEF Phase 2
Completed NCT01919177 - Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity Phase 2
Recruiting NCT03465072 - Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT03269630 - New Orleans Pulmonary Hypertension Biobank N/A
Recruiting NCT03327649 - Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction N/A
Not yet recruiting NCT03541603 - Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Phase 2